This page is updated frequently with new Vaccine-related patent applications.
| Swine virus vaccines that are liquid stable|
The present invention is drawn to liquid stable swine vaccines that comprise a live porcine virus. The invention is also drawn to the manufacture of such vaccines and methods of vaccinating animal subjects with these vaccines..
| Cytomegalovirus vaccines and methods of production|
Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising cmv isolated from epithelial cells are also disclosed..
The Trustees Of Princeton University
| Vaccine compositions|
The present disclosure provides vaccine compositions for prophylaxis and treatment of zika virus infections comprising zika virus antigens in immunogenic compositions, and in combination of zika antigens with one or more arbovirus antigens such as chikungunya virus and japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.. .
Bharat Biotech International Limited
| Prostate cancer vaccine|
Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer.
Wisconsin Alumni Research Foundation
| Methods of use for therapeutics targeting the pathogen porphyromonas gingivalis|
The invention relates to compositions, formulations, vaccines and antibodies for the prevention and/or treatment of aging and brain disorders, including alzheimer's disease, diabetes, cardiovascular disease, retinal disorders and arthritis. The invention also provides methods of treatment of aging disorders, brain disorders, including alzheimer's disease, diabetes, cardiovascular disease, retinal disorders, and arthritis by administering compositions, formulations, vaccines and antibodies described in the specification.
| Nasal vaccine for streptococcus pneumoniae|
The present invention provides a nasal vaccine for streptococcus pneumoniae, and a production method therefor. This nasal vaccine formulation for primates includes a complex of pspa, i.e.
| Inactivated whole virion vaccine-containing microneedle array preparation and administering the same|
Provided is a microneedle. The microneedle array includes a needle portion, which contains an inactivated whole virion influenza vaccine, and a sheet portion.
National University Corporation Hokkaido University
|Predicting response to epigenetic drug therapy|
The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy.
The Johns Hopkins University
|Uspa2 protein constructs and uses thereof|
The present invention relates to compositions comprising moraxella catarrhalis (m. Catarrhalis) ubiquitous surface protein a2 (uspa2).
Glaxosmithkline Biologicals Sa
|Methods and compositions for nanoemulsion vaccine formulations|
The present disclosure relates to nanoemulsion vaccine compositions and methods of making and using the same. The disclosed compositions and methods provide a means of treating, preventing, or protecting an individual from anthrax exposure or poisoning..
Vaccine delivery systems using yeast cell wall particles
The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines..
Orbis Health Solutions, Llc
Peptide vaccine therapy for treatment of fra-expressing tumors
Provided are methods for inducing and maintaining protective immunity against a tumor expressing frα in a subject, comprising the administration of one or more peptide vaccines according to a particular dosages or particular dosage regimens.. .
Galena Biopharma, Inc.
Cgap-pna multivalent peptide nucleic acid ligand display
Described herein are compositions composed of peptide nucleic acid strands. In some aspects the peptide nucleic acid strands are complementary to at least a portion of another peptide nucleic acid strand that may have one or more gamma substituents, where the ratio of pna strands is least 1:1.
The Usa, As Represented By The Secretary, Depart- Ment Of Health And Human Services
Plasmid, method and kit thereof for producing heat labile enterotoxin b-subunit
The present invention provides a plasmid, method and kit for producing heat labile enterotoxin b-subunit based on a bacillus subtilis expression system. By comparing with the conventional method in the art, the present invention has the advantages of high safety, good yield, and simplified process and is therefore favorable for the commercialization object of heat labile enterotoxin b-subunit in the application of vaccine adjuvant..
Agricultural Technology Research Institute
Toxoid preparation and uses thereof
The present invention relates to toxoid preparations comprising a non-disrupted and/or a non-denatured toxin associated with a particulate vector that minimizes or precludes said toxin from inflicting damage at an action site of said toxin. The present invention also relates to immunogenic compositions or vaccines comprising the toxoid preparations, and the methods of using the toxoid preparations, immunogenic compositions or vaccines..
Arytha Biosciences, Llc
Novel meningococcal conjugate vaccine for groups a, c, y and w135 and a preparation method thereof
The present invention provides a meningococcal conjugate vaccine for groups a, c, y and w135, which is a tetravalent conjugate vaccine comprising polysaccharide-protein conjugates obtained by respectively conjugating a capsular polysaccharide of neisseria meningitides groups a, c, y and w135 to a outer membrane vesicle protein selected from a group consisting of neisseria meningitides group b serotypes 4 and 15 outer membrane vesicle proteins. The meningococcal conjugate vaccine provided by the present invention may effectively avoid the risk of affecting the immune response to vaccines resulting from immune tolerance and competition between antigenic sites existing in multivalent conjugate vaccines prepared from a single carrier protein; the meningococcal conjugate vaccine provided by the present invention may avoid the safety risk of allergic reactions, toxicity reversion and the like which exist in conjugate vaccines prepared by using tt and dt as carrier proteins; and the meningococcal conjugate vaccine provided by the present invention may enhance immunity to neisseria meningitides group a and provide a bactericidal antibody having relatively extensive protective effect against neisseria meningitides group b.
Beijing Sanroad Biological Products Co., Ltd.
Method for emulsifying a triepitope peptide with montanide and kits for performing the same
The present invention relates to a method for preparing a vaccine formulation with an optimized polypeptide comprising three epitopes and montanide as adjuvant, for use in anti-cancer immunotherapy for administration to a human subject.. .
Dna vaccines encoding heat shock proteins
A method of treating a t cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (hsp 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (iddm) or rheumatoid arthritis.
Alma Bio Therapeutics
Kidney-specific tumor vaccine directed against kidney tumor antigen g-250
This invention provides an anti-cancer immunogenic agent(s) (e.g. Vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a g250 antigenic marker.
The Regents Of The University Of California
Novel composition of matter and stimulating the growth of beneficial microorganisms
The invention describes a novel composition of matter obtained from the leaves of green plants, which is useful in promoting the growth of beneficial microorganisms. Specifically, that the invention describes a hydrolysate prepared from plant leaf biomass (leaf biomass hydrolysate or “lbh”) which dramatically stimulates the growth of beneficial microorganisms.
University Of Maryland, College Park
Live, attenuated vaccines and methods of making and using
A live, attenuated hiv vaccine is provided, and methods of making a attenuated hiv vaccine are provided.. .
Method of producing an inactivated lentivirus, especially hiv, vaccine, kit and use
A novel method for producing an immunogenic composition or vaccine comprising inactivated lentivirus, in particular inactivated hiv, wherein producer cells producing, preferably constituvely producing lentivirus particles are provided, the lentivirus particles are produced by these producer cells in the presence of an antiretroviral (arv) agent which is an inhibitor of the in-ledgf/p75 interaction, the inactivated lentivirus is recovered and formulated in a pharmaceutically acceptable vehicle or carrier. The invention also relates to immunogenic compositions or vaccines and to methods for the therapeutic or prophylactic treatment of a mammal, especially a human, and various therapy combinations involving the administration of said immunogenic compositions or vaccines..
Therapies, vaccines, and predictive methods for infectious salmon anemia virus
The present invention provides therapies, vaccines, and predictive methods for infectious salmon anemia virus and provides compounds for diagnosing, preventing, and treating outbreaks of infectious salmon anemia virus including compounds for diagnosing, preventing, and treating infectious salmon anemia across different strains of virus.. .
Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
Described herein are dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus e-glycoproteins optionally further include mutations that introduce a strong cd4 t cell epitope.
The Government Of The U.s.a. As Rep. By The Secretary Of The Department Of Health And Human Se
Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
The present invention encompasses recombinant porcine reproductive and respiratory syndrome virus (prrsv) vaccines or compositions. In particular, the invention encompasses recombinant adenovirus vectors encoding and expressing prrsv gp2, gp3, gp4, gp5a, gp5 and/or e antigens, proteins, epitopes or immunogens.
Portable device for nucleic acid-based authentication of liquid samples
Methods and portable detection systems are provided herein that allow for authentication of liquid samples that have been manufactured to include an authentication code consisting of two or more single-stranded nucleic acid markers. The authenticating nucleic acid can be detected without the need for sequencing.
Methods and compositions for treating solid tumors and enhancing tumor vaccines
The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of etrb, et-1, icam-1, or another protein found herein to play a role in homing of t cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of t cells to a solid tumor, or a nucleotide molecule encoding same..
The Trustees Of The University Of Pennsylvania
Identification of cxcr8, a novel chemokine receptor
Method of treating a subject for a disorder that correlates to increased cxcr8 signaling. The method includes disrupting the activation of receptor cxcr8 by ligand cxcl17 in the subject.
The Regents Of The University Of California
Hjurp peptides and vaccines including the same
Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic t cell inducibility of the original sequence.
Oncotherapy Science, Inc.
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
The present invention relates to proteins and nucleic acids derived from staphylococcus aureus as well as therapeutic and diagnostic uses of the proteins and nucleic acids.. .
Evaxion Biotech Aps
Immunogenic wt-1 peptides and methods of use thereof
This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a wt1-expressing cancer, comprising same.. .
Sloan Kettering Institute For Cancer Research
Avirulent, immunogenic flavivirus chimeras
Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus.
Live attenuated virus vaccines for la crosse virus and other bunyaviridae
The invention relates to vaccine compositions including cev serogroup immunogens, attenuated and inactivated viruses of the cev serogroup and chimeric bunyaviridae. Also disclosed are methods of treating or preventing cev serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a cev serogroup immunogen, methods for detecting la crosse virus (lacy) infection in a biological sample and infectious chimeric bunyaviridae..
The U.s.a, As Represented By The Secretary, Department Of Health And Human Services
Immunogenic compositions comprising lawsonia intracellularis
The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of ppe caused by l. Intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
Boehringer Ingelheim Vetmedica, Inc.
T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation
A vaccine contains a long-chain peptide antigen having a plurality of epitopes. An interepitope sequence located between two of the plurality of epitopes contains two to ten consecutive tyrosines, two to ten consecutive threonines, two to ten consecutive alanines, two to ten consecutive histidines, two to ten consecutive glutamines or two to ten consecutive asparagines.
Cancer vaccine composition
A cancer vaccine composition for human leukocyte antigen (hla)-a*0206-positive persons, comprising a protein product of the tumor suppressor gene wt1 or a partial peptide thereof.. .
International Institute Of Cancer Immunology, Inc.
Methods for introducing mutations that alter the probability of intranucleic acid base pairing of a conserved structured nucleotide and related compositions
The present invention relates generally to methods for introducing mutations that alter the probability of intranucleic acid base pairing of a conserved structured nucleotide in a nucleic acid. The present invention also provide methods for making mutant pathogenic organisms suitable as live attenuated vaccines, animal and human diagnostics, and for identifying suitable drug targets..
Influenza virus vaccines and uses thereof
The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin ha1 domain that comprises an ha1 n-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an ha1 c-terminal stem segment, and (b) an influenza hemagglutinin ha2 domain, wherein on or more amino acids in the ha2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza..
Janssen Vaccines & Prevention B.v.
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
The instant invention provides for novel lipid nanoparticle (lnp) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide lnp formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g.
Merck Sharp & Dohme Corp
Influenza virus vaccines and uses thereof
Provided herein are chimeric influenza hemagglutinin (ha) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.. .
Icahn School Of Medicine At Mount Sinai
Acinetobacter baumannii antigens and the uses thereof
The present invention relates to an isolated polypeptide antigen of acinetobacter baumannii, comprising at least an amino acid sequence selected from the group consisting of: (a) seq id nos: 1-5; (b) an amino acid sequence having at least 80% sequence identity to seq id nos: 1, 3, 4 or 5; (c) an amino acid sequence having at least 60% sequence identity to seq id no: 2; and (d) a fragment of the amino acid sequence according to (a) to (c); wherein the polypeptide having the amino acid sequence according to (b) to (d) has immunostimulatory activity. The universal polypeptide antigens of acinetobacter baumannii can be used in the universal vaccine preparation.
National Chung Hsing University
Dock-and-lock (dnl) vaccines for cancer therapy
The present invention concerns methods and compositions for forming anti-cancer vaccine dnl complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine dnl complex comprises an antibody moiety that binds to dendritic cells, such as an anti-cd74 antibody or antigen-binding fragment thereof, attached to an ad (anchoring domain) moiety and a xenoantigen, such as cd20, attached to a ddd (dimerization and docking domain) moiety, wherein two copies of the ddd moiety form a dimer that binds to the ad moiety, resulting in the formation of the dnl complex.
Ibc Pharmaceuticals, Inc.
Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including psa, psma, steap and psca antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens psa, psma, steap and psca, as well as genetic constructs/vectors and vaccines expressing the sequences.
Inovio Pharmaceuticals, Inc.
Dna vector and transformed tumor cell vaccines
Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with s.